Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Recursion (NASDAQ: RXRX) announced it will release its Q3 2024 business updates and financial results on November 6, 2024, after market close. The company will not hold its regular earnings call for Q3. Instead, Recursion plans to host an update call on November 20, 2024, following the expected completion of its proposed business combination with Exscientia. The call will be streamed live on Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube, with opportunities for Q&A.
Recursion (NASDAQ: RXRX) ha annunciato che rilascerà i suoi aggiornamenti aziendali e risultati finanziari per il terzo trimestre del 2024 il 6 novembre 2024, dopo la chiusura del mercato. L'azienda non terrà la consueta conferenza sugli utili per il terzo trimestre. Invece, Recursion prevede di organizzare una chiamata di aggiornamento il 20 novembre 2024, dopo il completamento previsto della sua combinazione aziendale proposta con Exscientia. La chiamata sarà trasmessa in diretta sulle piattaforme social di Recursion, tra cui X (ex Twitter), LinkedIn e YouTube, con opportunità per domande e risposte.
Recursion (NASDAQ: RXRX) anunció que publicará sus actualizaciones comerciales y resultados financieros del tercer trimestre de 2024 el 6 de noviembre de 2024, después del cierre del mercado. La compañía no llevará a cabo su habitual llamada de ganancias para el tercer trimestre. En su lugar, Recursion planea organizar una llamada de actualización el 20 de noviembre de 2024, tras la finalización esperada de su propuesta de combinación empresarial con Exscientia. La llamada se transmitirá en vivo en las redes sociales de Recursion, incluyendo X (anteriormente Twitter), LinkedIn y YouTube, con oportunidades para preguntas y respuestas.
Recursion (NASDAQ: RXRX)는 2024년 3분기 사업 업데이트와 재무 결과를 2024년 11월 6일, 시장 마감 후에 발표할 것이라고 발표했습니다. 회사는 3분기 정기 실적 전화 회의를 개최하지 않을 예정입니다. 대신, Recursion은 Exscientia와의 사업 조합 제안 완료 이후인 2024년 11월 20일에 업데이트 전화를 개최할 계획입니다. 이 전화는 Recursion의 소셜 미디어 플랫폼인 X(이전의 Twitter), LinkedIn, YouTube에서 생중계되며, 질문과 답변의 기회도 제공됩니다.
Recursion (NASDAQ: RXRX) a annoncé qu'elle publiera ses mises à jour commerciales et résultats financiers pour le troisième trimestre 2024 le 6 novembre 2024, après la clôture du marché. L'entreprise ne tiendra pas sa conférence trimestrielle habituelle sur les résultats. Au lieu de cela, Recursion prévoit d'organiser un appel de mise à jour le 20 novembre 2024, après l'achèvement prévu de sa combinaison d'entreprise proposée avec Exscientia. L'appel sera diffusé en direct sur les plateformes de médias sociaux de Recursion, y compris X (anciennement Twitter), LinkedIn et YouTube, avec des opportunités de questions-réponses.
Recursion (NASDAQ: RXRX) gab bekannt, dass es seine Geschäftsupdates und finanziellen Ergebnisse für das 3. Quartal 2024 am 6. November 2024 nach Börsenschluss veröffentlichen wird. Das Unternehmen wird keine reguläre Gewinnanruf-Konferenz für das 3. Quartal abhalten. Stattdessen plant Recursion, am 20. November 2024 einen Aktualisierungsanruf zu veranstalten, nach dem voraussichtlichen Abschluss seiner vorgeschlagenen Unternehmenszusammenlegung mit Exscientia. Der Anruf wird live über die sozialen Medien von Recursion, einschließlich X (ehemals Twitter), LinkedIn und YouTube, gestreamt, wobei die Möglichkeit für Fragen und Antworten besteht.
- Upcoming business combination with Exscientia indicates strategic growth initiative
- None.
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia
Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets.
The company will not host its normal L(earnings) Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host an update call after the anticipated close of the proposed business combination with Exscientia, which is expected to be on Nov 20, 2024. We will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts and there will be opportunities to ask questions of the company.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; the anticipated closing of the proposed business combination with Exscientia; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Additional Information and Where to Find It.
This communication relates to the proposed business combination by and between Recursion and Exscientia plc. Recursion and Exscientia have delivered a definitive joint proxy statement related to the proposed business combination to Recursion’s stockholders and Exscientia’s shareholders, which was also filed with the SEC on October 10, 2024. The definitive joint proxy statement provides full details of the proposed business combination and the attendant benefits and risks, including the terms and conditions of the Scheme of Arrangement and the other information required to be provided to Exscientia’s shareholders under the applicable provisions of the United Kingdom Companies Act 2006. This communication is not a substitute for the definitive joint proxy statement or any other document that Recursion or Exscientia may file with the SEC or send to their respective security holders in connection with the proposed business combination. Security holders are urged to read the definitive joint proxy statement and all other relevant documents filed with the SEC or sent to Recursion’s stockholders or Exscientia’s shareholders as they become available because they will contain important information about the proposed business combination. All documents, when filed, will be available free of charge at the SEC’s website (www.sec.gov). You may also obtain these documents by contacting Recursion’s Investor Relations department at investor@recursion.com; or by contacting Exscientia’s Investor Relations department at investors@exscientia.ai. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (WHICH INCLUDES AN EXPLANATORY STATEMENT IN RESPECT OF THE SCHEME OF ARRANGEMENT OF EXSCIENTIA, IN ACCORDANCE WITH THE REQUIREMENTS OF THE UNITED KINGDOM COMPANIES ACT 2006) AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
Participants in the Solicitation.
The Company, Exscientia and their respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed business combination.
Information about Recursion’s directors and executive officers is available in Recursion’s proxy statement dated April 23, 2024 for its 2024 Annual Meeting of Stockholders. Information about Exscientia’s directors and executive officers is available in Exscientia’s Annual Report on Form 20-F dated March 21, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the definitive joint proxy statement. Investors are urged to read the definitive joint proxy statement and any other relevant materials to be filed with the SEC regarding the proposed business combination when they become available, carefully before making any voting or investment decisions.
No Offer or Solicitation.
This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Company securities issued in the proposed business combination are anticipated to be issued in reliance upon an available exemption from such registration requirements pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
FAQ
When will Recursion (RXRX) release Q3 2024 earnings?
When is Recursion's (RXRX) business combination with Exscientia expected to close?